NCT03263403 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Recomm Rep. 1997 Feb 14;46(RR-5):1-10.
Crum-Cianflone N, Sullivan E
Meningococcal Vaccinations. Infect Dis Ther. 2016 Jun;5(2):89-112. doi: 10.1007/s40121-016-0107-0. Epub 2016 Apr 16. Review.
Hart CA, Thomson AP
Meningococcal disease and its management in children. BMJ. 2006 Sep 30;333(7570):685-90. Review.
Hossain MA, Ahmed D, Ahmed T, Islam N, Breiman RF
Increasing isolations of Neisseria meningitides serogroup A from blood and cerebrospinal fluid in Dhaka, Bangladesh, 1999-2006. Am J Trop Med Hyg. 2009 Apr;80(4):615-8.
Memish ZA
Meningococcal disease and travel. Clin Infect Dis. 2002 Jan 1;34(1):84-90. Epub 2001 Nov 20.
Stephens DS, Greenwood B, Brandtzaeg P
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007 Jun 30;369(9580):2196-2210. doi: 10.1016/S0140-6736(07)61016-2. Review.
Vyse A, Wolter JM, Chen J, Ng T, Soriano-Gabarro M
Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol Infect. 2011 Jul;139(7):967-85. doi: 10.1017/S0950268811000574. Epub 2011 Apr 15. Review.

A Randomized Observer-blinded Controlled Non-inferiority Trial to Evaluate the Immunogenicity of Locally Manufactured Meningococcal ACWY Vaccine 'Ingovax ACWY' in Bangladeshi Healthy Adults.

Details for clinical trial NCT03263403

Clinical trial NCT03263403 - References